2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
149 hedge funds and large institutions have $505M invested in 2seventy bio in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 30 reducing their positions, and 22 closing their positions.
184% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $407K
103% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 30
1% more funds holding
Funds holding: 147 → 149 (+2)
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
1% less capital invested
Capital invested by funds: $508M → $505M (-$3.26M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.2M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$12.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.3M |
| 4 |
BlackRock
New York
|
+$10.3M |
| 5 |
Millennium Management
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.7M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$8.86M |
| 4 |
NM
Newtyn Management
New York
|
-$8.12M |
| 5 |
AG
Artal Group
Luxembourg
|
-$7.65M |
TSVT Hedge Fund Activity: Q2 2023 in Review
149 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q2 2023, worth a combined $505M — down 0.64% from $508M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TSVT positions and 22 closed out — a net gain of 2 holders — while 61 added to existing stakes and 30 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $14.2M. The largest seller was Citadel Advisors, cutting an estimated $22.9M.
- 149 institutional investors held 2seventy bio (TSVT) as of Q2 2023, up from 147 in Q1 2023.
- Funds reported $505M of 2seventy bio stock for Q2 2023, down 0.64% quarter-over-quarter.
- 24 funds opened new 2seventy bio positions in Q2 2023 and 22 closed out, a net change of +2 holders.
- The largest 2seventy bio buyer in Q2 2023 was Avidity Partners Management, an estimated $14.2M added.
- The largest 2seventy bio seller in Q2 2023 was Citadel Advisors, an estimated $22.9M sold.
Based on aggregated 13F filings for Q2 2023.